A recently developed genetic test to predict a man's risk for prostate cancer could reduce the need for repeat biopsies in men who have had a negative biopsy, data from a new study indicate.
A recently developed genetic test to predict a man’s risk for prostate cancer could reduce the need for repeat biopsies in men who have had a negative biopsy, data from a new study indicate.
Results of the study were published online in European Urology (May 12, 2012).
“The genetic test outperformed the PSA test in assessing cancer risk,” said co-investigator Karim Kader, MD, PhD, of the University of California, San Diego School of Medicine. “If results of this blood test were factored into prostate cancer predictors such as total free PSA, free PSA, number of core samples taken at biopsy, and family history, we would have a more accurate picture of whether or not a man is likely to develop the sometimes fatal disease.”
Dr. Kader and researchers from Wake Forest University School of Medicine in Winston-Salem, NC evaluated 1,654 men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) clinical trial. All the men had biopsies and consented to genetic studies that looked for the presence of germline single nucleotide polymorphisms.
“Avoiding repeat procedures, particularly in older men, can help reduce the risk of infection and potential hospitalizations,” said Dr. Kader. “The genetic score is available at any time in a man’s lifetime and could be used as a pre-screening test, thus leaving aggressive PSA screening to men at a higher genetic risk.”
One of the study’s co-authors is an employee of GlaxoSmithKline.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.